{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T16:41:17Z","timestamp":1766508077548,"version":"3.48.0"},"reference-count":44,"publisher":"American Society of Hematology","issue":"24","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,23]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Monoclonal gammopathy (MG) in chronic lymphocytic leukemia (CLL) portends heterogeneous outcomes, yet its molecular drivers and therapeutic implications remain undefined. In this retrospective analysis of 2075 patients with CLL (1999-2024), MG was detected in 18.47% cases, with immunoglobulin M (IgM) (8.18%), IgG (8.09%), light-chain (1.14%), and IgA (1.06%) subtypes demonstrating divergent clinicogenomic profiles. Patients with IgA-MG were older at diagnosis, whereas those with IgG-MG had a younger age and a higher frequency of mutated immunoglobulin heavy-chain variable (IGHV). In contrast, IgM-MG was associated with unmutated IGHV, elevated lactate dehydrogenase and \u03b22-microglobulin levels, higher frequencies of TP53 aberrations, and enrichment of MYD88, BIRC3, and DDX3X mutations. IgG-MG was associated with shorter time-to-first treatment (TTFT) only, whereas IgM-MG correlated with significantly inferior TTFT, progression-free survival, and overall survival. Subgroup analyses revealed that the adverse prognostic impact of MG was pronounced in IGHV-mutated CLL but attenuated in unmutated cases. Prognostic discrimination by the CLL-International Prognostic Index (CLL-IPI) remained robust regardless of MG status. Notably, patients with IgM-MG did not experience significant survival benefit from targeted therapy compared with conventional regimens. These findings demonstrate that MG subtypes, particularly IgM-MG, define biologically and clinically distinct subsets of CLL. Given the limited efficacy of Bruton tyrosine kinase inhibitors in IgM-MG, immunofixation-based MG profiling may inform risk-adapted treatment strategies and personalized therapy selection.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025017057","type":"journal-article","created":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:00:03Z","timestamp":1756926003000},"page":"6279-6291","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Monoclonal gammopathy defines distinct clinical subsets in chronic lymphocytic leukemia across therapeutic eras"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9355-2984","authenticated-orcid":false,"given":"Yuting","family":"Yan","sequence":"first","affiliation":[{"name":"1Department of Hematology, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China"},{"name":"2Department of Hematology, Tianjin Institutes of Health Science, Tianjin, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0284-754X","authenticated-orcid":false,"given":"Bolin","family":"Yuan","sequence":"additional","affiliation":[{"name":"3Department of Hematology, School of Clinical Medicine, Shandong Second Medical University, Weifang, China"},{"name":"4Department of Hematology, Shengli Oilfield Central Hospital, Dongying, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tonglu","family":"Qiu","sequence":"additional","affiliation":[{"name":"5Department of Hematology, Key Laboratory of Nanjing Medical University, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guoqiang","family":"Liu","sequence":"additional","affiliation":[{"name":"3Department of Hematology, School of Clinical Medicine, Shandong Second Medical University, Weifang, China"},{"name":"4Department of Hematology, Shengli Oilfield Central Hospital, Dongying, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weihao","family":"Chen","sequence":"additional","affiliation":[{"name":"1Department of Hematology, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China"},{"name":"2Department of Hematology, Tianjin Institutes of Health Science, Tianjin, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tingyu","family":"Wang","sequence":"additional","affiliation":[{"name":"1Department of Hematology, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China"},{"name":"2Department of Hematology, Tianjin Institutes of Health Science, Tianjin, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Yu","sequence":"additional","affiliation":[{"name":"1Department of Hematology, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China"},{"name":"2Department of Hematology, Tianjin Institutes of Health Science, Tianjin, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjie","family":"Xiong","sequence":"additional","affiliation":[{"name":"1Department of Hematology, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China"},{"name":"2Department of Hematology, Tianjin Institutes of Health Science, Tianjin, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4922-4614","authenticated-orcid":false,"given":"Gang","family":"An","sequence":"additional","affiliation":[{"name":"1Department of Hematology, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China"},{"name":"2Department of Hematology, Tianjin Institutes of Health Science, Tianjin, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8135-4913","authenticated-orcid":false,"given":"Dehui","family":"Zou","sequence":"additional","affiliation":[{"name":"1Department of Hematology, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China"},{"name":"2Department of Hematology, Tianjin Institutes of Health Science, Tianjin, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianyong","family":"Li","sequence":"additional","affiliation":[{"name":"5Department of Hematology, Key Laboratory of Nanjing Medical University, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9317-5253","authenticated-orcid":false,"given":"Liang","family":"Wang","sequence":"additional","affiliation":[{"name":"3Department of Hematology, School of Clinical Medicine, Shandong Second Medical University, Weifang, China"},{"name":"4Department of Hematology, Shengli Oilfield Central Hospital, Dongying, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6291-812X","authenticated-orcid":false,"given":"Shuhua","family":"Yi","sequence":"additional","affiliation":[{"name":"1Department of Hematology, State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China"},{"name":"2Department of Hematology, Tianjin Institutes of Health Science, Tianjin, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2025,12,10]]},"reference":[{"issue":"11","key":"2025122309561437200_bib1","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1001\/jama.2023.1946","article-title":"Diagnosis and treatment of chronic lymphocytic leukemia: a review","volume":"329","author":"Shadman","year":"2023","journal-title":"JAMA"},{"issue":"18","key":"2025122309561437200_bib2","doi-asserted-by":"crossref","first-page":"4440","DOI":"10.3390\/cancers15184440","article-title":"Serum paraprotein is associated with adverse prognostic factors and outcome, across different subtypes of mature B-cell malignancies-a systematic review","volume":"15","author":"Cox","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"20","key":"2025122309561437200_bib3","doi-asserted-by":"crossref","first-page":"4182","DOI":"10.1182\/blood-2012-05-427534","article-title":"Self-antigen recognition by follicular lymphoma B-cell receptors","volume":"120","author":"Sachen","year":"2012","journal-title":"Blood"},{"issue":"3","key":"2025122309561437200_bib4","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1182\/blood-2009-06-228015","article-title":"Gastric MALT lymphoma B cells express polyreactive, somatically mutated immunoglobulins","volume":"115","author":"Craig","year":"2010","journal-title":"Blood"},{"issue":"7","key":"2025122309561437200_bib5","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1182\/blood-2007-11-125450","article-title":"A new perspective: molecular motifs on oxidized LDL, apoptotic cells, and bacteria are targets for chronic lymphocytic leukemia antibodies","volume":"111","author":"Lanemo Myhrinder","year":"2008","journal-title":"Blood"},{"issue":"3","key":"2025122309561437200_bib6","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/ajcp\/87.3.385","article-title":"Monoclonal proteins in chronic lymphocytic leukemia","volume":"87","author":"Noel","year":"1987","journal-title":"Am J Clin Pathol"},{"issue":"8","key":"2025122309561437200_bib7","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.leukres.2010.12.005","article-title":"Prognostic significance of serum immunoglobulin paraprotein in patients with chronic lymphocytic leukemia","volume":"35","author":"Xu","year":"2011","journal-title":"Leuk Res"},{"issue":"12","key":"2025122309561437200_bib8","first-page":"1243","article-title":"Clinical significance of monoclonal proteins in chronic lymphocytic leukemia","volume":"6","author":"Bernstein","year":"1992","journal-title":"Leukemia"},{"issue":"6","key":"2025122309561437200_bib9","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1111\/bjh.16975","article-title":"Monoclonal gammopathy and serum immunoglobulin levels as prognostic factors in chronic lymphocytic leukaemia","volume":"190","author":"Corbingi","year":"2020","journal-title":"Br J Haematol"},{"key":"2025122309561437200_bib10","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/j.1600-065X.1979.tb00297.x","article-title":"Differentiation capacity and other properties of the leukemic cells of chronic lymphocytic leukemia","volume":"48","author":"Fu","year":"1979","journal-title":"Immunol Rev"},{"issue":"4","key":"2025122309561437200_bib11","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1136\/jcp.37.4.463","article-title":"Serum paraproteins in chronic lymphocytic leukaemia","volume":"37","author":"Sinclair","year":"1984","journal-title":"J Clin Pathol"},{"issue":"2","key":"2025122309561437200_bib12","first-page":"206","article-title":"Biclonal IgM gammopathy in chronic lymphocytic leukemia","volume":"112","author":"Schaffner","year":"1988","journal-title":"Arch Pathol Lab Med"},{"issue":"2","key":"2025122309561437200_bib13","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1002\/1097-0142(19880115)61:2<279::AID-CNCR2820610215>3.0.CO;2-4","article-title":"Serum immunoglobulins in B-chronic lymphocytic leukemia. Natural history and prognostic significance","volume":"61","author":"Rozman","year":"1988","journal-title":"Cancer"},{"issue":"1","key":"2025122309561437200_bib14","first-page":"52","article-title":"Low molecular weight IgM in the sera of patients with chronic lymphocytic leukemia","volume":"25","author":"Xu","year":"1993","journal-title":"Pathology"},{"issue":"2","key":"2025122309561437200_bib15","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/leu.2014.198","article-title":"IgM peak independently predicts treatment-free survival in chronic lymphocytic leukemia and correlates with accumulation of adverse oncogenetic events","volume":"29","author":"Rizzo","year":"2015","journal-title":"Leukemia"},{"issue":"6","key":"2025122309561437200_bib16","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.3324\/haematol.2020.263228","article-title":"Serum monoclonal component in chronic lymphocytic leukemia: baseline correlations and prognostic impact","volume":"106","author":"Mozas","year":"2021","journal-title":"Haematologica"},{"issue":"4","key":"2025122309561437200_bib17","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1309\/FDGWB5C2MYRYXH2E","article-title":"Chronic lymphocytic leukemia\/small lymphocytic lymphoma associated with IgM paraprotein","volume":"123","author":"Yin","year":"2005","journal-title":"Am J Clin Pathol"},{"issue":"14","key":"2025122309561437200_bib18","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/bloodadvances.2018026591","article-title":"IgA levels at diagnosis predict for infections, time to treatment, and survival in chronic lymphocytic leukemia","volume":"3","author":"Ishdorj","year":"2019","journal-title":"Blood Adv"},{"issue":"6","key":"2025122309561437200_bib19","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1038\/s41375-018-0344-1","article-title":"IgA hypogammaglobulinemia predicts outcome in chronic lymphocytic leukemia","volume":"33","author":"Reda","year":"2019","journal-title":"Leukemia"},{"key":"2025122309561437200_bib20","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.leukres.2017.02.011","article-title":"Clinical relevance of hypogammaglobulinemia, clinical and biologic variables on the infection risk and outcome of patients with stage A chronic lymphocytic leukemia","volume":"57","author":"Mauro","year":"2017","journal-title":"Leuk Res"},{"issue":"7","key":"2025122309561437200_bib21","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.3109\/10428194.2016.1142082","article-title":"Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia is a predictor of early death","volume":"57","author":"Andersen","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"17","key":"2025122309561437200_bib22","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1002\/cncr.29438","article-title":"Hypogammaglobulinemia in newly diagnosed chronic lymphocytic leukemia: natural history, clinical correlates, and outcomes","volume":"121","author":"Parikh","year":"2015","journal-title":"Cancer"},{"issue":"1","key":"2025122309561437200_bib23","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/bjh.15146","article-title":"Humoral immune failure defined by immunoglobulin class and immunoglobulin G subclass deficiency is associated with shorter treatment-free and overall survival in chronic lymphocytic leukaemia","volume":"181","author":"Crassini","year":"2018","journal-title":"Br J Haematol"},{"issue":"2","key":"2025122309561437200_bib24","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/s41375-019-0590-x","article-title":"Monitoring the cytogenetic architecture of minimal residual plasma cells indicates therapy-induced clonal selection in multiple myeloma","volume":"34","author":"An","year":"2020","journal-title":"Leukemia"},{"issue":"13","key":"2025122309561437200_bib25","doi-asserted-by":"crossref","first-page":"4049","DOI":"10.1182\/bloodadvances.2022007279","article-title":"Landscape of immunoglobulin heavy chain gene repertoire and its clinical relevance to LPL\/WM","volume":"6","author":"Wang","year":"2022","journal-title":"Blood Adv"},{"issue":"23","key":"2025122309561437200_bib26","doi-asserted-by":"crossref","first-page":"5483","DOI":"10.1158\/1078-0432.CCR-23-3939","article-title":"Determination of MYD88 and CXCR4 mutations for clinical detection and their significance in Waldenstr\u00f6m macroglobulinemia","volume":"30","author":"Yan","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2025122309561437200_bib27","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1038\/s41375-021-01124-5","article-title":"High incidence of MYD88 and KMT2D mutations in Chinese with chronic lymphocytic leukemia","volume":"35","author":"Yi","year":"2021","journal-title":"Leukemia"},{"issue":"6","key":"2025122309561437200_bib28","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(16)30029-8","article-title":"An International Prognostic Index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data","volume":"17","author":"International CLL-IPI Working Group","year":"2016","journal-title":"Lancet Oncol"},{"issue":"3","key":"2025122309561437200_bib29","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/ajh.27546","article-title":"Chronic lymphocytic leukemia: 2025 update on the epidemiology, pathogenesis, diagnosis, and therapy","volume":"100","author":"Hallek","year":"2025","journal-title":"Am J Hematol"},{"issue":"24","key":"2025122309561437200_bib30","doi-asserted-by":"crossref","first-page":"4928","DOI":"10.1182\/blood-2009-08-237651","article-title":"Evidence of serum immunoglobulin abnormalities up to 9.8 years before diagnosis of chronic lymphocytic leukemia: a prospective study","volume":"114","author":"Tsai","year":"2009","journal-title":"Blood"},{"issue":"3","key":"2025122309561437200_bib31","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41408-019-0186-8","article-title":"Elevated IgM and abnormal free light chain ratio are increased in relatives from high-risk chronic lymphocytic leukemia pedigrees","volume":"9","author":"Glenn","year":"2019","journal-title":"Blood Cancer J"},{"issue":"3","key":"2025122309561437200_bib32","doi-asserted-by":"crossref","first-page":"e394","DOI":"10.1038\/bcj.2015.28","article-title":"Waldenstrom macroglobulinemia: prognosis and management","volume":"5","author":"Oza","year":"2015","journal-title":"Blood Cancer J"},{"issue":"8","key":"2025122309561437200_bib33","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1002\/ajh.26595","article-title":"TP53-altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor-based therapy: a retrospective analysis","volume":"97","author":"Cherng","year":"2022","journal-title":"Am J Hematol"},{"issue":"5","key":"2025122309561437200_bib34","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1182\/blood.2023019634","article-title":"High karyotypic complexity is an independent prognostic factor in patients with CLL treated with venetoclax combinations","volume":"142","author":"F\u00fcrstenau","year":"2023","journal-title":"Blood"},{"key":"2025122309561437200_bib35","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-3837426\/v1","article-title":"Mutations detected in real world clinical sequencing during BTK inhibitor treatment in CLL","author":"Brown","year":"2024","journal-title":"Res Sq"},{"issue":"2","key":"2025122309561437200_bib36","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/bjh.18418","article-title":"Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non-Hodgkin lymphoma","volume":"200","author":"Nakhoda","year":"2023","journal-title":"Br J Haematol"},{"issue":"12","key":"2025122309561437200_bib37","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1182\/bloodadvances.2022008821","article-title":"BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib","volume":"7","author":"Bonfiglio","year":"2023","journal-title":"Blood Adv"},{"issue":"16","key":"2025122309561437200_bib38","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1182\/blood-2017-11-817296","article-title":"Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide","volume":"131","author":"Takahashi","year":"2018","journal-title":"Blood"},{"issue":"23","key":"2025122309561437200_bib39","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1182\/blood.V126.23.2907.2907","article-title":"Comprehensive genetic characterization of 17p deleted CLL identifies predictors of overall survival","volume":"126","author":"Yu","year":"2015","journal-title":"Blood"},{"issue":"22","key":"2025122309561437200_bib40","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.3390\/cells13221839","article-title":"Association of genomic alterations with the presence of serum monoclonal proteins in chronic lymphocytic leukemia","volume":"13","author":"Pi\u00f1eyroa","year":"2024","journal-title":"Cells"},{"issue":"18","key":"2025122309561437200_bib41","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood.2020006844","article-title":"A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstrom macroglobulinemia: the ASPEN study","volume":"136","author":"Tam","year":"2020","journal-title":"Blood"},{"issue":"5","key":"2025122309561437200_bib42","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/bjh.12067","article-title":"Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia","volume":"159","author":"Oscier","year":"2012","journal-title":"Br J Haematol"},{"issue":"1","key":"2025122309561437200_bib43","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3109\/10428194.2012.706285","article-title":"Immunoglobulin G subclass deficiency and infection risk in 150 patients with chronic lymphocytic leukemia","volume":"54","author":"Freeman","year":"2013","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"2025122309561437200_bib44","doi-asserted-by":"crossref","first-page":"537","DOI":"10.3109\/00365548.2013.769279","article-title":"Clinical significance of serum immunoglobulin G subclass deficiency in patients with chronic lymphocytic leukemia","volume":"45","author":"Svensson","year":"2013","journal-title":"Scand J Infect Dis"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/24\/6279\/2474204\/blooda_adv-2025-017057-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/24\/6279\/2474204\/blooda_adv-2025-017057-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T14:56:23Z","timestamp":1766501783000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/24\/6279\/547090\/Monoclonal-gammopathy-defines-distinct-clinical"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,10]]},"references-count":44,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2025,12,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025017057","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"type":"print","value":"2473-9529"},{"type":"electronic","value":"2473-9537"}],"subject":[],"published-other":{"date-parts":[[2025,12,23]]},"published":{"date-parts":[[2025,12,10]]}}}